Immunomedics, Inc. ’s (IMMU) share price has entered into oversold territory with an RSI value of 28.9. The Zacks Consensus Estimate on Immunomedics, Inc.’s earnings for the full year period has loss of 0.00 cents over the past two months to $-0.13 per share. Currently, Immunomedics, Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (IMMU) after its recent drop.
IMMUNOMEDICS INC (IMMU): Free Stock Analysis Report
Zacks Investment Research
- Personal Investing Ideas & Strategies
- Finance Trading